| |
| |
|
| Insider
Information: |
Nelsen Robert |
| Relationship: |
10% Owner |
| City: |
Chicago |
| State: |
IL |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
34 |
|
| Direct
Shares |
34,307,145 |
|
|
Indirect Shares
|
122,760,866 |
|
|
| Direct
Value |
$496,270,318 |
|
|
|
Indirect Value
|
$1,052,795,645 |
|
|
| Total
Shares |
157,068,011 |
|
|
| Total
Value |
$1,549,065,963 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
17
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
17
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-17.0
|
0.0
|
| Percentage
Gain/Loss : |
 -17.5%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Adolor Corp |
ADLR |
Director |
2007-05-17 |
1,207,523 |
2003-12-08 |
402,874 |
Premium* |
|
|
Illumina Inc |
ILMN |
Director |
2004-02-03 |
11,423 |
2004-02-03 |
2,915,298 |
Premium* |
|
|
Alnylam Pharmaceuticals Inc |
ALNY |
10% Owner |
|
0 |
2004-05-27 |
222,500 |
Premium* |
|
|
Cyclacel Pharmaceuticals Inc |
CYCC |
Director, 10% Owner |
2004-03-19 |
0 |
2004-03-19 |
2,054,271 |
Premium* |
|
|
Neurogesx Inc |
NGSX |
Director, 10% Owner |
2011-07-21 |
4,187,777 |
2011-07-26 |
4,187,777 |
Premium* |
|
|
Trubion Pharmaceuticals, Inc |
TRBN |
10% Owner |
2010-10-28 |
0 |
2010-10-28 |
0 |
Premium* |
|
|
Kythera Biopharmaceuticals Inc |
KYTH |
Former Director |
2015-03-24 |
10,295 |
2015-03-13 |
947,309 |
Premium* |
|
|
Receptos, Inc. |
RCPT |
10% Owner |
2014-05-14 |
2,058,634 |
|
0 |
Premium* |
|
|
Bluebird Bio, Inc. |
BLUE |
10% Owner |
2013-06-24 |
1,793,588 |
2013-06-24 |
0 |
Premium* |
|
|
Agios Pharmaceuticals Inc |
AGIO |
Director |
2017-02-28 |
109,230 |
2017-02-28 |
40,599 |
Premium* |
|
|
Fate Therapeutics Inc |
FATE |
Director, 10% Owner |
2013-10-04 |
0 |
2013-10-04 |
2,473,188 |
Premium* |
|
|
Achaogen Inc |
AKAO |
10% Owner |
2014-03-17 |
1,418,657 |
2014-03-17 |
0 |
Premium* |
|
|
Sage Therapeutics, Inc. |
SAGE |
Director |
2015-11-09 |
107,950 |
2015-11-09 |
1,124,699 |
Premium* |
|
|
VBI Vaccines Inc |
VBIV |
10% Owner |
2015-08-17 |
3,397,830 |
|
0 |
Premium* |
|
|
Juno Therapeutics, Inc. |
JUNO |
Director |
2018-03-05 |
0 |
2018-03-05 |
0 |
Premium* |
|
|
Bellerophon Therapeutics Inc |
BLPH |
Director, 10% Owner |
|
0 |
2015-02-19 |
965,660 |
Premium* |
|
|
Pulmatrix Inc |
PULM |
Former 10% owner |
2015-06-15 |
0 |
2018-04-03 |
3,436,456 |
Premium* |
|
|
Adesto Technologies Corp |
IOTS |
10% Owner |
2015-10-30 |
2,276,511 |
2015-10-26 |
0 |
Premium* |
|
|
Syros Pharmaceuticals, Inc. |
SYRS |
10% Owner |
2019-07-17 |
4,242,051 |
2016-07-06 |
4,637,137 |
Premium* |
|
|
Impinj Inc |
PI |
10% Owner |
2016-07-26 |
1,366,735 |
2016-07-26 |
0 |
Premium* |
|
|
Sienna Biopharmaceuticals, Inc. |
SNNA |
10% Owner |
2017-08-01 |
0 |
2019-02-22 |
1,865,800 |
Premium* |
|
|
Q32 Bio Inc |
QTTB |
10% Owner |
2019-05-21 |
5,768,694 |
2018-04-02 |
6,068,695 |
Premium* |
|
|
Denali Therapeutics Inc. |
DNLI |
Director |
2021-06-02 |
12,432 |
2021-06-02 |
9,668,749 |
Premium* |
|
|
Quanterix Corp |
QTRX |
10% Owner |
2020-11-24 |
1,889 |
2020-11-24 |
1,214,770 |
Premium* |
|
|
Unity Biotechnology Inc |
UBX |
Director, 10% Owner |
2018-05-07 |
0 |
2018-05-07 |
1,682,417 |
Premium* |
|
|
Twist Bioscience Corp |
TWST |
10% Owner |
2018-11-02 |
0 |
2018-11-02 |
954,146 |
Premium* |
|
|
Karuna Therapeutics, Inc. |
KRTX |
Director, 10% Owner |
2021-04-13 |
5,269 |
2021-04-13 |
1,456,435 |
Premium* |
|
|
Vir Biotechnology, Inc. |
VIR |
Director, 10% Owner |
2023-05-22 |
576,148 |
2023-05-22 |
12,950,556 |
Premium* |
|
|
Beam Therapeutics Inc. |
BEAM |
10% Owner |
2021-06-30 |
28,111 |
2021-06-30 |
2,921,519 |
Premium* |
|
|
908 Devices Inc. |
MASS |
10% Owner |
2020-12-22 |
5,725,045 |
2020-12-22 |
0 |
Premium* |
|
|
Sana Biotechnology, Inc. |
SANA |
Director, 10% Owner |
2024-02-08 |
1,353 |
2024-02-08 |
22,759,772 |
Premium* |
|
|
Lyell Immunopharma, Inc. |
LYEL |
Director, 10% Owner |
2021-06-21 |
0 |
2021-06-21 |
18,206,358 |
Premium* |
|
|
Prime Medicine, Inc. |
PRME |
Director, 10% Owner |
2022-10-24 |
0 |
2024-02-15 |
15,472,674 |
Premium* |
|
|
Neumora Therapeutics, Inc. |
NMRA |
10% Owner |
2023-09-22 |
0 |
2023-11-14 |
4,131,207 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
238 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 10
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ALNY |
Alnylam Pharmaceuticals I... |
10% Owner |
– – • |
2004-05-27 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
222,500 |
|
- |
|
| RCPT |
Receptos, Inc. |
10% Owner |
– – • |
2013-05-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
114,285 |
|
- |
|
| VBIV |
VBI Vaccines Inc |
10% Owner |
– – • |
2014-07-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,399,253 |
|
- |
|
| JUNO |
Juno Therapeutics, Inc. |
Director |
– • • |
2014-12-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,097,015 |
|
- |
|
| BLPH |
Bellerophon Therapeutics ... |
Director |
– • • |
2015-02-13 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
752,994 |
|
- |
|
| VBIV |
VBI Vaccines Inc |
10% Owner |
– – • |
2015-08-17 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
3,397,830 |
|
- |
|
| SYRS |
Syros Pharmaceuticals, In... |
Director |
– • • |
2016-06-29 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
213,333 |
|
- |
|
| VIR |
Vir Biotechnology, Inc. |
Director |
– • • |
2019-10-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
444,444 |
|
- |
|
| SANA |
Sana Biotechnology, Inc. |
Director |
– • – |
2021-02-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
292,500 |
|
- |
|
| SANA |
Sana Biotechnology, Inc. |
|
– • – |
2022-04-05 |
4 |
A |
$0.00 |
$0 |
D/D |
230 |
230 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
Director |
– • – |
2018-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
237 |
54,058 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
Director |
– • – |
2017-10-05 |
4 |
A |
$0.00 |
$0 |
D/D |
254 |
53,821 |
0 |
- |
|
| SANA |
Sana Biotechnology, Inc. |
|
– • – |
2022-07-05 |
4 |
A |
$0.00 |
$0 |
D/D |
266 |
496 |
0 |
- |
|
| SANA |
Sana Biotechnology, Inc. |
|
– • • |
2022-10-05 |
4 |
A |
$0.00 |
$0 |
D/D |
321 |
817 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
Director |
– • • |
2016-04-05 |
4 |
A |
$0.00 |
$0 |
D/D |
329 |
51,153 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
Director |
– • • |
2016-07-05 |
4 |
A |
$0.00 |
$0 |
D/D |
335 |
51,488 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
Director |
– • • |
2017-07-05 |
4 |
A |
$0.00 |
$0 |
D/D |
400 |
53,567 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
Director |
– • • |
2016-10-05 |
4 |
A |
$0.00 |
$0 |
D/D |
447 |
51,935 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
Director |
– • • |
2017-04-05 |
4 |
A |
$0.00 |
$0 |
D/D |
573 |
53,167 |
0 |
- |
|
| KYTH |
Kythera Biopharmaceutical... |
Director |
– • – |
2014-06-27 |
4 |
A |
$0.00 |
$0 |
D/D |
584 |
1,759 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
Director |
– • • |
2017-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
659 |
52,594 |
0 |
- |
|
| ILMN |
Illumina Inc |
Director |
– • • |
2003-11-26 |
4 |
A |
$0.00 |
$0 |
D/D |
770 |
10,395 |
|
- |
|
| KYTH |
Kythera Biopharmaceutical... |
Director |
– • – |
2014-08-14 |
4 |
A |
$0.00 |
$0 |
D/D |
783 |
2,542 |
0 |
- |
|
| ILMN |
Illumina Inc |
Director |
– • – |
2004-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,028 |
11,423 |
|
- |
|
| KYTH |
Kythera Biopharmaceutical... |
Director |
– • – |
2014-03-20 |
4 |
A |
$0.00 |
$0 |
D/D |
1,175 |
1,175 |
0 |
- |
|
238 Records found
|
|
Page 1 of 10 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
